{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-100980","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.937500+00:00","generated_at":"2026-05-17T02:49:11.489499+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incannex Healthcare gets Nasdaq bid price compliance extension to April 20, 2026","bullets":["Received second 180-day grace period from Nasdaq until April 20, 2026 to regain $1 minimum bid price.","Failed bid price requirement; transferred to Nasdaq Capital Market on July 10, 2025.","Must close at $1 or above for 10 consecutive business days during extension to comply.","Company intends to cure deficiency via reverse stock split if necessary.","Listing on Nasdaq Capital Market continues; no immediate delisting effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-100980","json":"https://secwatch.observer/filing/0001213900-25-100980.json","markdown":"https://secwatch.observer/filing/0001213900-25-100980.md","text":"https://secwatch.observer/filing/0001213900-25-100980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/ea0262074-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:49:11.489499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aceb532c5c26121896006e2d89fec70e39bc30d2","claim":"Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"April 20, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this Second Grace Period","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","confidence":0.82}],"comparable_filings":[{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001104659-26-057974","ticker":"HUMA","company_name":"Humacyte, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057974","json":"https://secwatch.observer/filing/0001104659-26-057974.json","markdown":"https://secwatch.observer/filing/0001104659-26-057974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 4, 2026, Humacyte, Inc. (the “Company”)\nreceived a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification\nthat, for the 30 consecutive business days ended May 1, 2026, th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm"}},{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}},{"accession":"0001213900-26-061113","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-26T21:28:49+00:00","headline":"Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061113","json":"https://secwatch.observer/filing/0001213900-26-061113.json","markdown":"https://secwatch.observer/filing/0001213900-26-061113.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/0001213900-26-061113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/ea0292140-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 21, 2026, Evolution Metals & Technologies\nCorp. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The\nNasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/0001213900-26-061113-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001829126-26-005568","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-21T20:15:19+00:00","headline":"Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices","event_type":"other_material","sec_items":["2.02","3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005568","json":"https://secwatch.observer/filing/0001829126-26-005568.json","markdown":"https://secwatch.observer/filing/0001829126-26-005568.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 20, 2026 (the\n“Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the\nStaff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held\nshares and all other Nasdaq initial listing standards, with the exception of the Bid Price Requirement, and (ii) the Company’s written\nnotice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.\nIf at any time during this Second Grace Period","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025100980/0001213900-25-100980-index.htm","comparable_excerpt":"reviously disclosed, on May\n8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together\nwith the May 15 Notice, the “ Notices ”). In connection with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}